New brain cancer drug combo tested for first time in humans
Disease control
Recruiting now
This early-phase study tests a new drug called MT-125 given alongside standard radiation for people with a newly diagnosed, aggressive brain tumor called glioblastoma. The main goals are to find a safe dose and check for side effects. About 36 adults aged 18 and older with a spec…
Phase: PHASE1, PHASE2 • Sponsor: Myosin Therapeutics Inc. • Aim: Disease control
Last updated May 07, 2026 18:39 UTC